<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122769</url>
  </required_header>
  <id_info>
    <org_study_id>2016-003453-15</org_study_id>
    <nct_id>NCT03122769</nct_id>
  </id_info>
  <brief_title>Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography</brief_title>
  <official_title>Cardiac Uptake of Metformin and Expression of Metformin Membrane Transporter Proteins in the Human Failing Myocardium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Wiggers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if metformin is taken up into the failing myocardium.
      Recent experimental and epidemiological studies have shown beneficial effects of metformin on
      heart failure. It is unknown whether this effect is direct or indirect.

      The aim of the study is to investigate if metformin is taken up in heart failure using a
      novel 11C-metformin tracer and positron emission tomography (PET).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">April 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All 6 subjects allocated to the study will receive 11C-metformin intravenously.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin uptake in the failing myocardium</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac uptake is evaluated through analysis of acquired PET-images.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <arm_group>
    <arm_group_label>11C-metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants allocated to the study will be included in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>11C-metformin</intervention_name>
    <description>200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography</description>
    <arm_group_label>11C-metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic heart failure, Left Ventricular Ejection Fraction &lt;45%

          -  New York Heart Association (NYHA) class I, II, III

          -  Relatively preserved renal function (eGFR &gt; 30 ml/min)

          -  Ability to understand the written patient information and to give informed consent

          -  Negative p-HCG for women of childbearing potential

        Exclusion Criteria:

          -  Known allergy to metformin

          -  Age &lt; 18 years

          -  Current abuse of alcohol or drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Cardiology, Palle Juul-Jensens Boulevard 99</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Wiggers</investigator_full_name>
    <investigator_title>Senior consultant, associate professor, MD, PhD, DMSc</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Organic cation transporter</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

